RxDoctor Payments Data

Jennifer Champagne, NP

Adult Health · Picayune, MSNPI 1235529454

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 59 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations.

$1,051in general payments, 2019–2025

Across 59 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$185
  • Mylan Specialty L.p.$155
  • Novartis$127
  • Amgen$115
  • Exact Sciences$84
  • Daiichi Sankyo Inc.$75
  • plus $311 from 12 others

What the payments were for

  • Food & beverage$1,051100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,051 in reported general payments places this provider in the 60th percentile of 93 adult health providers in Mississippi.

See all adult health providers in Mississippi

Medicare billing

Part B allowed, 2024
$23,577
Medicare patients
89
Services billed
465

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol28$26,268
RybelsusSemaglutide18$24,376
MyrbetriqMirabegron32$23,069
JardianceEmpagliflozin12$19,955
VraylarCariprazine Hcl13$17,974
EliquisApixaban14$12,764
XareltoRivaroxaban19$11,867
LinzessLinaclotide18$9,434
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,378
GemtesaVibegron12$5,594
Albuterol Sulfate HfaAlbuterol Sulfate84$3,243
Arnuity ElliptaFluticasone Furoate11$2,191
Levothyroxine Sodium105$1,271
Ventolin HfaAlbuterol Sulfate13$1,259
Gabapentin72$1,180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Linzess$185$27,40831 claims
AstraZenecaFarxiga$41$26,26828 claims
Novo NordiskRybelsus$37$24,37618 claims
GSKTrelegy Ellipta, Arnuity Ellipta$16$11,56924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 93 adult health providers in Mississippi.

Other adult health in Picayune

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →